Marvel Biosciences Corp Stock Price, News & Analysis

Marvel Biosciences (TSXV: MRVL, OTCQB: MBCOF) has released partial final data from its preclinical Rett syndrome study comparing its lead compound MB-204 with Trofinetide, the only FDA and Health Canada approved treatment for the condition.

The study, conducted with the iBraiN Institute, demonstrated that MB-204 (10 mg/kg oral daily) significantly outperformed Trofinetide (100 mg/kg injected daily) across multiple endpoints in Mecp2 mice over a two-week treatment period:

• MB-204 reversed social behavioral deficiencies in nose and paw touching (p<0.0001 vs control)
• MB-204 reversed impairments in following behaviour (p<0.0001 vs control)
• Both treatments improved social preference behaviour in the three-chamber test
• MB-204 reversed spontaneous alternations and same arm returns in Y-maze test (p<0.0001 vs control)

Analysis of the carry-over effects is ongoing and will be released separately. The company plans to publish and present the data at an upcoming scientific conference.

Marvel Biosciences Corp (TSXV: MRVL) (OTCQB: MBCOF) has announced its participation in the upcoming Bloom Burton & Co. Healthcare Investor Conference, scheduled for May 5-6, 2025, at the Metro Toronto Convention Centre.

The conference will facilitate connections between U.S., Canadian, and international investors interested in Canadian healthcare developments. CEO Rod Matheson and CSO Mark Williams will deliver a group presentation and engage in one-on-one meetings with potential investors during the event.

Marvel Biosciences (TSXV: MRVL, OTCQB: MBCOF) has received a notice of allowance from the Chinese patent office for its lead compound MB-204, marking the first worldwide allowance for this patent family. MB-204 is a novel fluorinated derivative of Istradefylline, an approved Parkinson's drug, which Marvel is developing for neurological conditions including autism, depression, and Alzheimer's Disease.

The company has completed cGMP synthesis and 4-week GLP toxicology studies for MB-204 and is preparing for clinical trials. This patent allowance secures key composition of matter intellectual property protection in China, with the company anticipating similar notices from other countries.

Marvel Biosciences (TSXV: MRVL) (OTCQB: MBCOF) has reported promising new data from its preclinical Rett syndrome study of MB204, conducted with the iBraiN Institute. The study compared MB204 to Trofinetide, the only FDA and Health Canada approved Rett syndrome treatment. Key findings show MB204 demonstrated sustained post-treatment benefits lasting 21 days, outperforming Trofinetide's 14-day effects. The company plans to pursue FDA Orphan and rare disease designation for MB204, which could provide market exclusivity and other benefits. Full study results are expected in Q1 2025.

Marvel Biosciences has been awarded a $300,000 Alberta Innovates AICE Validates grant to support the preclinical validation of MB204 for Alzheimer's disease treatment. The company's drug candidate, MB204, is an adenosine A2A receptor antagonist designed to target the underlying pathology of Alzheimer's, rather than just managing symptoms. The company has completed cGMP synthesis and 4-week GLP toxicology studies, and will conduct a chronic long-term preclinical study to validate MB204's effectiveness before moving to Phase 1 clinical trials.

Marvel Biosciences (TSXV: MRVL, OTCQB: MBCOF) reported promising interim results from a preclinical study of MB204 as a potential treatment for Rett syndrome. Conducted by experts at the iBraiN Institute in France, the study showed that chronic oral dosing of MB204 restored social interaction behaviors to near-normal levels in a preclinical model of Rett syndrome. These improvements in cognitive function may represent a pivotal shift in therapy.

Led by Dr. Julie Le Merrer and Dr. Jerome Becker, the study found that 14 days of MB204 treatment (10 mg/kg oral dosing once daily) nearly reversed social and behavioral deficits. MB204 outperformed the approved drug Trofinetide (100 mg/kg via intraperitoneal injection once daily) on most studied endpoints and exhibited a distinct carry-over effect lasting at least 14 days after dosing cessation.

Marvel CSO Dr. Mark Williams noted that MB204 showed profound effects on restoring social behaviors, suggesting potential synaptic plasticity induction. Marvel CEO Rod Matheson emphasized the compelling nature of the data, hinting at improved therapies for Rett syndrome.

Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) has reported positive results from a study on MB204 in the Oprm1 mouse model of autism. The research, conducted by Drs. Julie Le Merrer and Jerome Becker, showed that a single oral dose of MB204 successfully reversed social behavior deficits typically seen in the model within one hour of administration.

Key findings include:

• A high dose (2.5 mg/kg) of MB204 significantly restored social behavior in all measured endpoints (p<0.0001)
• A lower dose (1 mg/kg) also reversed nearly all social behavior deficits
• The higher dose even outperformed normal (non-autistic) mice on several endpoints

The researchers noted that MB204 showed more improvement and a hyper-social effect compared to previously tested drugs. Marvel is now testing MB204 in other autism spectrum disorder models, including Rett syndrome (Mecp2) and Fragile X syndrome (Fmr1).

Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) has announced a collaboration with the FRAXA Research Foundation to test its lead asset MB204 in a preclinical model of Fragile X syndrome (FXS). FXS is a common cause of inherited intellectual disability, affecting approximately 1 in 4000 males and 1 in 8000 females. The collaboration aims to explore MB204's potential as a treatment for FXS and other forms of autism spectrum disorder.

MB204 is an adenosine A2a receptor antagonist and a novel fluorinated derivative of the approved anti-Parkinson's drug Istradefylline. FRAXA will test MB204 through its internal screening program this year. The foundation previously identified BPN14770, which is currently in Phase 3 trials for Fragile X. Notably, there is currently no approved drug to treat FXS.

Marvel Biosciences Corp. (TSXV: MRVL) has announced the grant of 1,475,000 incentive stock options to certain directors and officers. The options, approved on July 23, 2024, have an exercise price of $0.125 per share, matching the closing price on July 22, 2024. These options are exercisable until July 23, 2029, and will vest in three tranches: 1/3 immediately, 1/3 on the first anniversary, and 1/3 on the second anniversary of the grant. The stock options are subject to the company's stock option plan and TSX Venture Exchange requirements.